Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrik Brundin

Showing results (1-10 of 261) with videos related to

Pageof 27
Sort By:
Brain : a Journal of Neurology|September 24, 2002
GDNF treatment in Parkinson's disease: time for controlled clinical trials?Patrik Brundin
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 13, 2017
Prying into the Prion Hypothesis for Parkinson's DiseasePatrik Brundin, Ronald Melki
Parkinsonism & Related Disorders|January 20, 2010
Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's diseaseElodie Angot, Patrik Brundin
Neuron|October 15, 2003
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the eggAaron Ciechanover, Patrik Brundin
Nature Reviews. Neuroscience|December 4, 2002
Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synucleinJulie Lotharius, Patrik Brundin
Journal of Parkinson'S Disease|April 22, 2014
Is exenatide the next big thing in Parkinson's disease?Tanya Simuni, Patrik Brundin
Journal of Innate Immunity|September 4, 2017
Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal InfectionViviane Labrie, Patrik Brundin
Human Molecular Genetics|September 28, 2002
Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's diseaseJulie Lotharius, Patrik Brundin
Trends in Endocrinology and Metabolism: TEM|September 2, 2019
Lots of Movement in Gut and Parkinson's ResearchGabriela Mercado, Patrik Brundin
Expert Review of Neurotherapeutics|July 5, 2011
Can α-synuclein be targeted in novel therapies for Parkinson's disease?Patrik Brundin, Roger Olsson
Pageof 27

Showing results (1-10 of 261) with videos related to

Sort By:
Pageof 27
Brain : a Journal of Neurology|September 24, 2002
GDNF treatment in Parkinson's disease: time for controlled clinical trials?Patrik Brundin
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 13, 2017
Prying into the Prion Hypothesis for Parkinson's DiseasePatrik Brundin, Ronald Melki
Parkinsonism & Related Disorders|January 20, 2010
Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's diseaseElodie Angot, Patrik Brundin
Neuron|October 15, 2003
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the eggAaron Ciechanover, Patrik Brundin
Nature Reviews. Neuroscience|December 4, 2002
Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synucleinJulie Lotharius, Patrik Brundin
Journal of Parkinson'S Disease|April 22, 2014
Is exenatide the next big thing in Parkinson's disease?Tanya Simuni, Patrik Brundin
Journal of Innate Immunity|September 4, 2017
Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal InfectionViviane Labrie, Patrik Brundin
Human Molecular Genetics|September 28, 2002
Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's diseaseJulie Lotharius, Patrik Brundin
Trends in Endocrinology and Metabolism: TEM|September 2, 2019
Lots of Movement in Gut and Parkinson's ResearchGabriela Mercado, Patrik Brundin
Expert Review of Neurotherapeutics|July 5, 2011
Can α-synuclein be targeted in novel therapies for Parkinson's disease?Patrik Brundin, Roger Olsson
Pageof 27